COMP <GO>
SPTX vs JANX // 10Y YIELD & FRED MACRO BETA
Seaport Therapeutics Inc. (NASDAQ) VS. Janux Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SPTX 0
— JANX 2
■ METRIC PARITY
LAST: $20.01 (+2.09%) • MKT CAP: $1.05B
macro-sensitivity
—
LAST: $17.46 (-0.06%) • MKT CAP: $1.07B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPTX VS. JANX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPTX | JANX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -13.80% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.64% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.5 | 51.4 | -2.90 | JANX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.05B | $1.07B | -$18.9M | JANX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPTX REV | JANX REV | SPTX GROSS % | JANX GROSS % | SPTX FCF | JANX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $104.6M | $441.5M | — | — | — | -$83.3M |
| FY 2024 | — | $276.8M | — | — | — | -$44.2M |
| FY 2023 | — | $204.3M | — | — | — | -$50.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPTX // BETA —
JANX // BETA —